Key Insights

Highlights

Treatment Research

16 treatments under study, led by Cisplatin

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 1/2 (1)

Trial Status

Recruiting2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07552558Phase 1/2Not Yet Recruiting

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06997094Phase 1Recruiting

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

NCT06005324Phase 1RecruitingPrimary

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Cisplatin1
  • Questionnaire Administration1
  • External Beam Radiation Therapy1
  • Cetuximab1
  • Biospecimen Collection1

Active Sponsors

  • Mayo Clinic1
  • University of Chicago1
  • Bicara Therapeutics1
  • Washington University School of Medicine1

Top Investigators

Related Conditions

  • Resectable Head And Neck Squamouscell Carcinoma1
  • Human Papillomavirusnegative Neck Squamous Cell Carcinoma1
  • Resectable Human Papillomavirusindependent Head And Neck Mucosal Squamous Cell Carcinoma1
  • Head And Neck Squamous Cell Carcinoma1
  • Resectable Head And Neck Squamous Cell Carcinoma1

Activity Timeline